Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Complex Regional Pain Syndrome (CRPS) Market Snapshot (2023 to 2033)

The global demand for complex regional pain syndrome (CRPS) market is estimated to be worth around US$ 103.7 million in the current year 2023. During the projection period from 2023 to 2033, the market is forecasted to expand at a CAGR of 2.2%. The analysis report by FMI further predicts the market to expand positively during the forecast years rising to US$ 129.2 million by 2033.

The increase in the number of individuals suffering from complex regional pain syndrome (CRPS), chronic pain, and failing back syndrome is one of the significant reasons driving market development. Complex regional pain syndrome (CRPS) is a chronic pain disorder that can affect the entire body or only the legs, arms, feet, and hands.

There are two forms of CRPS, each with identical symptoms and treatments. Complex regional pain syndrome (CRPS) Type I arises after an injury without any nerve damage (also known as reflex sympathetic dystrophy). Type II CRPS develops as a result of particular nerve damage or trauma.

The prognosis of complicated regional pain syndrome varies by individual. In most situations, CRPS is minor, and the patient progressively heals over time; but, in other cases, the symptoms are severe, resulting in long-term impairment. Also, CRPS affects both men and women equally, however, women are more likely to be impacted.

The exact etiology of complex regional pain syndrome (CRPS) is unknown. CRPS is caused by an injury or trauma in around 90% of patients. Leg immobility, soft tissue damage, fracture, sprain, or needle stick injuries produced during surgical procedures are all typical causes of injury. Further, in individuals with CRPS, peripheral nerve abnormalities include unmyelinated and weakly myelinated nerve fibers at the axon area, which creates aberrant neurological symptoms.

CRPS tissue has an increased level of inflammatory molecules such as cytokines and it is frequent in people with inflammatory and autoimmune disorders. Currently, the genetic propensity to complex regional pain syndrome is not being studied extensively.

A study on the family incidence of CRPS in Dutch patients discovered that CRPS may occur in a familial form, but the inheritance pattern remained unknown. The number of symptoms and the individual's medical history influence the diagnosis of CRPS. There are just a few diagnostic procedures for CRPS.

According to the incidence statistics, females are three times more impacted than males. Additionally, according to research done in the United Kingdom, one in every 3,800 persons gets CRPS each year. Therapy (Rehabilitation Therapy, Psychotherapy) or pharmaceuticals such as non-steroidal anti-inflammatory drugs, corticosteroids, and others can be used to treat CRPS.

Attributes or Data Points Details
Global Complex Regional Pain Syndrome (CRPS) Market Valuation in 2022 US$ 101.9 million
Estimated Global Market Share in 2023 US$ 103.7 million
Forecasted Global Market Size by 2033 US$ 129.2 million
Projected Global Market Growth Rate from 2023 to 2033 2.2% CAGR
Historical Market Growth Rate from 2018 to 2022 1.4% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Complex Regional Pain Syndrome (CRPS) Demand Analysis (2018 to 2022) Vs. Market Outlook (2023 to 2033)

The global demand for complex regional pain syndrome (CRPS), in terms of value, was nearly US$ 95.1 million in the year 2018, according to FMI. During the years from 2018 to 2022, sales witnessed significant growth, registering a CAGR of 1.4%. By the end of the year 2022, the overall valuation of the market reached about US$ 101.9 million.

CRPS is more frequent in women and can occur at any age, according to the National Institute of Neurological Disorders and Stroke (NINDS). Furthermore, 90% of instances were caused by trauma or injury. As a result, several people suffering from chronic pain drive the market growth.

Growth in research and development spending by both private and governmental entities, as well as favorable government legislation, are some of the key drivers projected to drive the market in the next years. Moreover, the Worldwide Research Foundation for RDS/CRPS, for example, developed an international research network to help educate medical professionals and promote research.

Which are the Prominent Drivers of the Complex Regional Pain Syndrome (CRPS) Market?

A Growing Number of People Suffering from Chronic Pain to Boost Demand

There are currently no medications authorized by the USA FDA for the treatment of complex regional pain syndrome. Physicians, on the other hand, recommended therapy and medications to treat chronic pain.

The USA Food and Drug Administration recently identified Neridronic acid as a breakthrough drug in clinical studies for complex regional pain syndrome. Also, the FDA has granted the medicine Fast-track and orphan drug designations. Intense research and development, an increase in the number of CRPS cases, and the successful completion of clinical studies are expected to accelerate the expansion of the complex regional pain syndrome market.

The growing number of non-profit initiatives, increased research and development funding by private and public organizations, and various government initiatives to raise awareness about the syndrome are expected to drive market growth during the forecast period. For example,

  • The USA Pain Foundation, a non-profit organization, is committed to supporting persons who suffer from chronic pain disorders. The USA Pain Foundation aims to empower, educate, and connect those suffering from severe chronic diseases.

Rising research and development efforts and FDA approvals of new medications are likely to boost market expansion throughout the forecast period. For example,

  • The FDA awarded orphan drug classification to Soin Therapeutics, an Ohio-based pharmaceutical firm, in September 2021 for low-dosage Naltrexone (LDN) to treat Complex Regional Pain Syndrome (CRPS).
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Complex Regional Pain Syndrome (CRPS) Market?

Tight Regulatory Approval and High Medicine Costs to Hinder Market Growth

In the forthcoming years, tight regulatory approval and high medicine costs may limit the growth of the complex regional pain syndrome market. In addition to this, a dearth of in-depth knowledge of CRPS, a shortage of medical and behavioral pain management professionals, and a dearth of effective treatment choices are the primary challenges impeding the growth of the complex regional pain syndrome market. Furthermore, in poor nations, a dearth of information on the target ailment may limit market growth further.

Region-Wise Insights

Regional Market Comparison Global Market Share in Percentage
North America 58.5%
Europe 14.5%

How is the Complex Regional Pain Syndrome (CRPS) Business Likely to Expand across North America?

Patients' Increased Awareness of Disease Remittance Therapy Creating Opportunities for Complex Regional Pain Syndrome (CRPS) Manufacturers

North America is at the vanguard of regional growth and a significant revenue provider on a worldwide scale. Patients' increased awareness of disease remittance therapy, the expanding frequency of CRPS, and high public and private healthcare spending are all driving the region's rise.

Simple access to high-quality healthcare, good reimbursement regulations, a robust clinical pipeline, and the approval of innovative medications are the important reasons expected to drive revenue growth in North America. Additionally, the increased knowledge of disease remittance therapy among patients, the rising prevalence of CRPS, and high public and private healthcare spending are driving market expansion in these areas.

Simple access to high-quality healthcare, a robust clinical pipeline, and the approval of innovative medications are projected to boost market expansion in North America. Thus, due to the aforementioned reasons, North America possessed a 58.5% market share in 2022, registering a CAGR of 2.1% for the complex regional pain syndrome (CRPS) market in the assessment period between 2023 and 2033.

Regional Market Comparison Global Market Share in Percentage
The United States 48.7%
Germany 4.1%
Japan 3.2%

How is Asia Pacific Estimated to Create Growth Opportunities for the Complex Regional Pain Syndrome (CRPS) Market?

Increasing Number of Patients Fueling Significant Adoption

Asia Pacific is expected to be a significantly growing market throughout the projection period. As many people live in cities, several patients in the region are growing. This, combined with rising healthcare spending, is likely to push Asia Pacific’s market. Over the projected period, favorable regulatory rules for medication approval are expected to enhance demand for the regional market.

The key tactics followed by prominent companies in the worldwide complex regional pain syndrome (CRPS) market have been an expansion in emerging countries and a high emphasis on early diagnosis, screening, monitoring, and pharmacological clinical development. Thus, Asia Pacific procured a 35% market share in the year 2022.

Regional Markets CAGR (2023 to 2033)
The United Kingdom 1.4%
China 2.5%
India 2%
Australia 1.8%

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Which Therapy Type is in High Demand in the Complex Regional Pain Syndrome (CRPS)?

Drug-based Therapy to Remain Highly Sought after

Based on therapy type, drug-based therapy accounted for a great proportion of the complex regional pain syndrome (CRPS) market in 2020. This is mostly due to an increase in the prevalence of several forms of chronic pain, such as lower back pain, severe headache or migraine pain, and face discomfort.

The market for pain reliever medications is predicted to expand throughout the forecast period due to the world's expanding elderly population, sedentary lifestyle, and rising number of surgical operations. Thus, based on therapy type, drugs are anticipated to expand at a 2% CAGR in the complex regional pain syndrome (CRPS) market in the sales indicator period from 2023 to 2033.

Category By Therapy
Top Segment Therapy by Drugs
Market Share in Percentage 38.2%
Category By Distribution Channel
Top Segment Hospital Pharmacies
Market Share in Percentage 48.2%

Which is the Leading Distribution Channel in the Complex Regional Pain Syndrome (CRPS) Market?

The Hospital Pharmacy Category is Witnessing Huge Demand in the Complex Regional Pain Syndrome (CRPS) Systems Market

Based on end use, the hospital pharmacy category is predicted to expand at a notable rate in the market during the forecast period. Hospitals are the leading end, consumers of chronic pain treatment products, accounting for a significant market share of the market in 2020.

Pain management strategies are becoming increasingly common in hospitals, particularly for post-surgical pain. As a result of the increasing number of surgical operations worldwide, hospital pharmacy is likely to continue to generate strong demand for complex regional pain syndrome (CRPS).

The most common complex regional pain syndrome (CRPS) techniques are conducted in hospitals, notably for post-surgical pain, where the cost of monitoring and treating side effects creates a strong demand for complex regional pain syndrome (CRPS) medications and technologies. Thus, by distribution channel, the hospital pharmacy category is expected to hold the prominent market share for the complex regional pain syndrome (CRPS) market in the forecast period from 2023 to 2033.

Start-ups for Complex Regional Pain Syndrome (CRPS) Market

Key Startup Players Operating in the Complex Regional Pain Syndrome (CRPS) Market

  • Brazos Biomedical (TENS) Transcutaneous Electrical Nerve Stimulation: Transcutaneous electrical nerve stimulation technique stimulates muscles and nerves with small electrical pulses delivered through specific pads to relieve pain. When electricity strikes the nerve system, it disrupts pain signals traveling between the fibers and the brain. Also, such gadgets are compact and portable, bringing pain care to the patient's location.
  • Brazos Biomedical is a start-up established in the United States of America that provides wearable, holo-cephalic medical equipment. To treat migraine discomfort, the start-up’s technology electrically stimulates the trigeminal and occipital nerves. This non-invasive therapeutic method may give alleviate this medical problem that is underserved.

Nalu Medical- Spinal Cord Stimulation

Before reaching the brain, the spinal cord stimulation system gathers and suppresses pain impulses. This method consists of a tiny device that, like a pacemaker, sends electrical pulses to the spinal cord. Also, this assists patients in better managing chronic pain and reducing their reliance on opioid drugs.

Nalu Medical is a firm located in the United States of America that is working on an implanted medical device. Also, it is used as an additional treatment for people suffering from persistent pain in the trunk or limbs. The company also provides an External Trial Stimulator (ETS) for use during a Spinal Cord Stimulation (SCS) trial before implanting the permanent device.

Market Competition

Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc. Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LL. are among the leading companies operating in the market.

Recent Developments in the Complex Regional Pain Syndrome (CRPS) Market

  • In August 2022, GSK plc announced the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action. It may address the significant unmet medical needs of myelofibrosis patients with anemia, which had been accepted by the US Food and Drug Administration (FDA).
  • In June 2022, Mallinckrodt plc, a global biopharmaceutical company announced the resubmission of the Company's New Drug Application (NDA) to the USA Food and Drug Administration (FDA) for the investigational agent terlipressin. It helps to treat adults with hepatorenal syndrome (HRS), an acute and life-threatening condition with no FDA-approved treatment.

Report Scope

Report Attributes Details
Market Value in 2023 US$ 103.7 million
Market Value in 2033 US$ 129.2 million
Growth Rate CAGR of 2.2% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Therapy Type
  • Route Of Administration
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • The Middle East and Africa
Key Countries Profiled
  • The United States of America
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Japan
  • South Korea
  • India
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Mallinckrodt Pharmaceuticals
  • GlaxoSmithKline plc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie
  • ACTAVIS
  • Zydus Pharmaceuticals Inc.
  • Sandoz
  • Janssen Global Services LLC.
  • Medline Plus
Customization Available Upon Request

Key Segments Profiled in the Complex Regional Pain Syndrome (CRPS) Industry Survey

By Therapy Type:

  • Physical Therapy
  • Therapy via Drugs
    • Analgesics
    • Antidepressants
    • Corticosteroids
    • Others
  • Surgical Sympathectomy
  • Intrathecal Drug Pumps
  • Spinal Cord Stimulation

By Route of Administration:

  • Oral Therapy
  • Intravenous Therapy

By Distribution Channel:

  • Hospital Pharmacy
  • Drug Stores
  • Retail Pharmacy
  • E-Commerce

By Region:

  • North America
  • Latin America
  • Europe Complex
  • Asia Pacific
  • The Middle East and Africa

Frequently Asked Questions

What is the Expected Growth Rate of the Market?

The market may expand at a 2.2% CAGR from 2023 to 2033.

What was the Valuation of Market in 2022?

The market in 2022 recorded US$ 101.9 million.

What Country Shows High Lucrativeness?

China will exhibit a 2.5% CAGR throughout 2033.

Who are the Key Players in the Market?

AbbVie, ACTAVIS and Sandoz are the key players in this market.

How Did the Market Perform Historically?

From 2018 to 2022, the market rose at a 1.4% CAGR.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033

        5.3.1. Physical Therapy

        5.3.2. Therapy via Drugs

            5.3.2.1. Analgesics

            5.3.2.2. Antidepressants

            5.3.2.3. Corticosteroids

            5.3.2.4. Others

        5.3.3. Surgical Sympathectomy

        5.3.4. Intrathecal Drug Pumps

        5.3.5. Spinal Cord Stimulation

    5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral Therapy

        6.3.2. Intravenous Therapy

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacy

        7.3.2. Drug Stores

        7.3.3. Retail Pharmacy

        7.3.4. E-Commerce

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Therapy Type

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Therapy Type

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Therapy Type

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapy Type

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Therapy Type

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapy Type

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Therapy Type

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapy Type

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Therapy Type

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapy Type

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Therapy Type

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Therapy Type

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Therapy Type

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Therapy Type

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Therapy Type

            16.1.2.2. By Route of Administration

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Therapy Type

            16.2.2.2. By Route of Administration

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Therapy Type

            16.3.2.2. By Route of Administration

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Therapy Type

            16.4.2.2. By Route of Administration

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Therapy Type

            16.5.2.2. By Route of Administration

            16.5.2.3. By Distribution Channel

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Therapy Type

            16.6.2.2. By Route of Administration

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Therapy Type

            16.7.2.2. By Route of Administration

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Therapy Type

            16.8.2.2. By Route of Administration

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Therapy Type

            16.9.2.2. By Route of Administration

            16.9.2.3. By Distribution Channel

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Therapy Type

            16.10.2.2. By Route of Administration

            16.10.2.3. By Distribution Channel

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Therapy Type

            16.11.2.2. By Route of Administration

            16.11.2.3. By Distribution Channel

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Therapy Type

            16.12.2.2. By Route of Administration

            16.12.2.3. By Distribution Channel

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Therapy Type

            16.13.2.2. By Route of Administration

            16.13.2.3. By Distribution Channel

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Therapy Type

            16.14.2.2. By Route of Administration

            16.14.2.3. By Distribution Channel

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Therapy Type

            16.15.2.2. By Route of Administration

            16.15.2.3. By Distribution Channel

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Therapy Type

            16.16.2.2. By Route of Administration

            16.16.2.3. By Distribution Channel

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Therapy Type

            16.17.2.2. By Route of Administration

            16.17.2.3. By Distribution Channel

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Therapy Type

            16.18.2.2. By Route of Administration

            16.18.2.3. By Distribution Channel

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Therapy Type

            16.19.2.2. By Route of Administration

            16.19.2.3. By Distribution Channel

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Therapy Type

            16.20.2.2. By Route of Administration

            16.20.2.3. By Distribution Channel

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Therapy Type

            16.21.2.2. By Route of Administration

            16.21.2.3. By Distribution Channel

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Therapy Type

            16.22.2.2. By Route of Administration

            16.22.2.3. By Distribution Channel

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Therapy Type

            16.23.2.2. By Route of Administration

            16.23.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Therapy Type

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Mallinckrodt Pharmaceuticals

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. GlaxoSmithKline plc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Mylan N.V.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Teva Pharmaceutical Industries Ltd.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. AbbVie

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. ACTAVIS

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Zydus Pharmaceuticals Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Sandoz

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Janssen Global Services LLC.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Medline Plus

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Acrocallosal Syndrome Therapeutics Market

Published : January 2023

Healthcare

Central Pain Syndrome Management Market

Published : January 2023

Explore Healthcare Insights

View Reports

Complex Regional Pain Syndrome (CRPS) Market